FDX1 and cancer: Targeting Ferredoxin 1-mediated metabolic vulnerabilities could offer novel strategies to selectively inhibit tumor growth while sparing normal cells, thereby improving the efficacy of cancer treatment and overcoming therapeutic resistance.